Literature DB >> 32016672

Outcomes for a Large Cohort of Patients with Rectal Neuroendocrine Tumors: an Analysis of the National Cancer Database.

Beiqun Zhao1, Hannah M Hollandsworth1, Nicole E Lopez1, Lisa A Parry1, Benjamin Abbadessa1, Bard C Cosman1, Sonia L Ramamoorthy1, Samuel Eisenstein2.   

Abstract

BACKGROUND: Rectal neuroendocrine tumors comprise 20% of neuroendocrine tumors in the alimentary tract, but there is controversy surrounding the optimal management of this disease. The purpose of this study is to better define treatment for patients with rectal neuroendocrine tumors.
METHODS: Using the National Cancer Database, we analyzed patients with rectal neuroendocrine tumors between 2004 and 2015. Patients with metastatic disease and missing treatment data were excluded. We examined overall survival stratified by tumor size, treatment type, and presence of positive lymph nodes using Kaplan-Meier analysis with log-rank test. Cox proportional hazard regression model was performed to identify factors associated with overall survival.
RESULTS: In total, 17,448 patients with rectal neuroendocrine tumors were identified; 16,531 of these patients met inclusion criteria. The majority of patients had tumors ≤ 10 mm (9216 patients, 79.8%), and approximately 90% underwent local excision. The probability of 5-year overall survival was significantly higher for patients with smaller tumors (≤ 10 mm: 94.1% 11-20 mm: 85.7%, > 20 mm: 71.8%; p < 0.001) and those with no positive lymph nodes (91.4% versus 53.3%, p < 0.001). The probability of 5-year overall survival differed based on treatment modality (local excision: 93.6%, radical resection: 79.1%, observation alone: 77.1%; p < 0.001). On multivariable Cox regression, when compared to local excision, radical resection was not associated with a difference in overall survival but observation alone was associated with significantly worse OS (HR = 2.750, p < 0.001).
CONCLUSIONS: There is a significant difference in overall survival between patients who underwent local excision versus observation alone. Excision of the tumor should be offered to all patients with rectal neuroendocrine tumors who are appropriate surgical candidates, regardless of the tumor size.

Entities:  

Keywords:  Colorectal; Neuroendocrine; Outcomes; Surgery

Mesh:

Year:  2020        PMID: 32016672      PMCID: PMC7396292          DOI: 10.1007/s11605-020-04525-6

Source DB:  PubMed          Journal:  J Gastrointest Surg        ISSN: 1091-255X            Impact factor:   3.452


  18 in total

1.  Tumor size and depth predict rate of lymph node metastasis in colon carcinoids and can be used to select patients for endoscopic resection.

Authors:  Riad H Al Natour; Mandeep S Saund; Vivian M Sanchez; Edward E Whang; Ashish M Sharma; Qin Huang; Valia A Boosalis; Jason S Gold
Journal:  J Gastrointest Surg       Date:  2011-12-06       Impact factor: 3.452

2.  ENETS Consensus Guidelines Update for Colorectal Neuroendocrine Neoplasms.

Authors:  J K Ramage; W W De Herder; G Delle Fave; P Ferolla; D Ferone; T Ito; P Ruszniewski; A Sundin; W Weber; Z Zheng-Pei; B Taal; A Pascher
Journal:  Neuroendocrinology       Date:  2016-01-05       Impact factor: 4.914

3.  Carcinoid tumors of the rectum: a multi-institutional international collaboration.

Authors:  Conor J Shields; Emmanuel Tiret; Desmond C Winter
Journal:  Ann Surg       Date:  2010-11       Impact factor: 12.969

4.  Clinical outcomes for rectal carcinoid tumors according to a new (AJCC 7th edition) TNM staging system: a single institutional analysis of 122 patients.

Authors:  Min Sung Kim; Hyuk Hur; Byung Soh Min; Seung Hyuk Baik; Kang Young Lee; Nam Kyu Kim
Journal:  J Surg Oncol       Date:  2013-03-15       Impact factor: 3.454

5.  Treatment strategy for rectal carcinoids: a clinicopathological analysis of 229 cases at a single cancer institution.

Authors:  Akiyoshi Kasuga; Akiko Chino; Naoyuki Uragami; Teruhito Kishihara; Masahiro Igarashi; Rikiya Fujita; Noriko Yamamoto; Masashi Ueno; Masatoshi Oya; Tetsuichiro Muto
Journal:  J Gastroenterol Hepatol       Date:  2012-12       Impact factor: 4.029

6.  Lymph node size is not a reliable criterion for predicting nodal metastasis in rectal neuroendocrine tumours.

Authors:  B C Kim; Y E Kim; H J Chang; S H Lee; E G Youk; D-S Lee; J B Lee; E-J Lee; M J Kim; D K Sohn; J H Oh
Journal:  Colorectal Dis       Date:  2016-07       Impact factor: 3.788

Review 7.  One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States.

Authors:  James C Yao; Manal Hassan; Alexandria Phan; Cecile Dagohoy; Colleen Leary; Jeannette E Mares; Eddie K Abdalla; Jason B Fleming; Jean-Nicolas Vauthey; Asif Rashid; Douglas B Evans
Journal:  J Clin Oncol       Date:  2008-06-20       Impact factor: 44.544

8.  Rectal carcinoid tumors: review of results after endoscopic and surgical therapy.

Authors:  Mary R Kwaan; Joel E Goldberg; Ronald Bleday
Journal:  Arch Surg       Date:  2008-05

9.  A 5-decade analysis of 13,715 carcinoid tumors.

Authors:  Irvin M Modlin; Kevin D Lye; Mark Kidd
Journal:  Cancer       Date:  2003-02-15       Impact factor: 6.860

10.  Surgical management and outcome of rectal carcinoids in a university hospital.

Authors:  Rockson Wei; Oswens S H Lo; Wai Lun Law
Journal:  World J Surg Oncol       Date:  2015-02-07       Impact factor: 2.754

View more
  2 in total

1.  Grade G2 Rectal Neuroendocrine Tumor Is Much More Invasive Compared With G1 Tumor.

Authors:  Yi-Wei Li; Yi-Ping He; Fang-Qi Liu; Jun-Jie Peng; San-Jun Cai; Ye Xu; Ming-He Wang
Journal:  Front Oncol       Date:  2021-03-11       Impact factor: 6.244

2.  A small, low-grade rectal neuroendocrine tumor with lateral pelvic lymph node metastasis: a case report.

Authors:  Seonhui Shin; Young-In Maeng; Seyun Jung; Chun-Seok Yang
Journal:  Ann Coloproctol       Date:  2022-03-07
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.